Serina Therapeutics Book Value Per Share Growth & History (SER)
Serina Therapeutics's book value per share was -$0.46 for fiscal 2025.
View full Serina Therapeutics company overviewSerina Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$0.46 | -$0.53 | — |
| 2024 | 2024-12-31 | $0.07 | $471.35 | — |
| 2023 | 2023-12-31 | -$471.28 | $42,887.44 | — |
| 2022 | 2022-12-31 | -$43,358.72 | -$29,776.12 | — |
| 2021 | 2021-12-31 | -$13,582.61 | -$7,670.69 | — |
| 2020 | 2020-12-31 | -$5,911.92 | -$8,477.85 | — |
| 2019 | 2019-12-31 | $2,565.93 | -$6,486.62 | −71.66% |
| 2018 | 2018-12-31 | $9,052.55 | -$342.39 | −3.64% |
| 2017 | 2017-12-31 | $9,394.94 | — | — |
Serina Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.74 | $11.62 | — |
| Q1 2026 | 2026-03-31 | $0.85 | -$5.17 | −85.86% |
| Q4 2025 | 2025-12-31 | -$0.46 | -$0.53 | — |
| Q3 2025 | 2025-09-30 | -$10.61 | $43.87 | — |
| Q2 2025 | 2025-06-30 | -$10.88 | $54.58 | — |
| Q1 2025 | 2025-03-31 | $6.02 | $24.04 | — |
| Q4 2024 | 2024-12-31 | $0.07 | $471.35 | — |
| Q3 2024 | 2024-09-30 | -$54.48 | $31,547.47 | — |
| Q2 2024 | 2024-06-30 | -$65.46 | $25,383.72 | — |
| Q1 2024 | 2024-03-31 | -$18.01 | $41,432.87 | — |
| Q4 2023 | 2023-12-31 | -$471.28 | $42,887.44 | — |
| Q3 2023 | 2023-09-30 | -$31,601.95 | -$14,265.95 | — |
| Q2 2023 | 2023-06-30 | -$25,449.17 | -$10,277.06 | — |
| Q1 2023 | 2023-03-31 | -$41,450.88 | -$28,196.09 | — |
| Q4 2022 | 2022-12-31 | -$43,358.72 | -$29,776.12 | — |
| Q3 2022 | 2022-09-30 | -$17,336.01 | -$5,929.31 | — |
| Q2 2022 | 2022-06-30 | -$15,172.12 | -$5,698.17 | — |
| Q1 2022 | 2022-03-31 | -$13,254.80 | -$6,294.75 | — |
| Q4 2021 | 2021-12-31 | -$13,582.61 | -$7,670.69 | — |
| Q3 2021 | 2021-09-30 | -$11,406.70 | -$7,187.47 | — |
| Q2 2021 | 2021-06-30 | -$9,473.95 | -$6,647.24 | — |
| Q1 2021 | 2021-03-31 | -$6,960.05 | -$6,105.28 | — |
| Q4 2020 | 2020-12-31 | -$5,911.92 | -$8,477.85 | — |
| Q3 2020 | 2020-09-30 | -$4,219.23 | -$9,238.87 | — |
| Q2 2020 | 2020-06-30 | -$2,826.70 | -$10,636.02 | — |
| Q1 2020 | 2020-03-31 | -$854.76 | -$11,643.35 | — |
| Q4 2019 | 2019-12-31 | $2,565.93 | -$6,486.62 | −71.66% |
| Q3 2019 | 2019-09-30 | $5,019.64 | — | — |
| Q2 2019 | 2019-06-30 | $7,809.31 | — | — |
| Q1 2019 | 2019-03-31 | $10,788.59 | — | — |
| Q4 2018 | 2018-12-31 | $9,052.55 | -$342.39 | −3.64% |
| Q4 2017 | 2017-12-31 | $9,394.94 | — | — |
Serina Therapeutics book value per share trends
Over the last five fiscal years, Serina Therapeutics's book value per share increased from -$5,911.92 to -$0.46, a change of $5,911.46. The latest reported quarter, Q2 2026, shows $0.74.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Serina Therapeutics source filings ↗